C4 Therapeutics

Cemsidomide can become the lead value driver because an oral IKZF1/3 degrader with differentiated tolerability and anti-myeloma activity would give C4 a credible best-in-class route in multiple myeloma. If it holds, C4 owns a potentially registrational oncology asset; if it breaks, the company reverts to a much earlier-stage platform story.

Strategic collaborations can validate TORPEDO and subsidize discovery because large pharma partners are paying for access to C4’s degrader-design capabilities across multiple targets. If partner demand persists, C4 can fund more shots on goal and retain platform credibility; if partners leave, TORPEDO’s perceived moat weakens.

C4’s capital allocation only creates per-share value if its cash runway is long enough to reach clinical readouts before shareholders must fund the next stage on distressed terms. Clinical success can still fail owners if the company must dilute heavily before value-inflecting data.

CFT8919 gives C4 a capital-efficient second clinical option if Betta Pharma’s Greater China trial confirms that degrading EGFR L858R resistance mutations has clinical utility. A positive partner-run trial would broaden C4 beyond cemsidomide; a failure would concentrate the equity story back into one lead asset.